Browse > Article
http://dx.doi.org/10.5483/BMBRep.2016.49.4.220

Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses  

Jung, Byeongjin (College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Kang, Hyejin (College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Lee, Wonhwa (College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Noh, Hyun Jin (Department of Biochemistry and Department of Biomedical Sciences, Ajou University School of Medicine)
Kim, You-Sun (Department of Biochemistry and Department of Biomedical Sciences, Ajou University School of Medicine)
Han, Min-Su (Laboratory for Arthritis and Bone Biology, Fatima Research Institute, Fatima Hospital)
Baek, Moon-Chang (Department of Molecular Medicine, CMRI, School of Medicine, Kyungpook National University)
Kim, Jaehong (Department of Biochemistry, School of Medicine, Gachon University)
Bae, Jong-Sup (College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Publication Information
BMB Reports / v.49, no.4, 2016 , pp. 214-219 More about this Journal
Abstract
A nucleosomal protein, high mobility group box 1 (HMGB1) is known to be a late mediator of sepsis. Dabrafenib is a B-Raf inhibitor and initially used for the treatment of metastatic melanoma therapy. Inhibition of HMGB1 and renewal of vascular integrity is appearing as an engaging therapeutic strategy in the administration of severe sepsis or septic shock. Here, we examined the effects of dabrafenib (DAB) on the modulation of HMGB1-mediated septic responses. DAB inhibited the release of HMGB1 and downregulated HMGB1-dependent inflammatory responses by enhancing the expressions of cell adhesion molecules (CAMs) in human endothelial cells. In addition, treatment with DAB inhibited the HMGB1 secretion by CLP and sepsis-related mortality and pulmonary injury. This study demonstrated that DAB could be alternative therapeutic options for sepsis or septic shock via the inhibition of the HMGB1 signaling pathway.
Keywords
Barrier integrity; Dabrafenib; HMGB1; Sepsis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Bernard GR, Vincent JL, Laterre PF et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344, 699-709   DOI
2 Russell JA (2006) Management of sepsis. N Engl J Med 355, 1699-1713   DOI
3 Andreu Ballester JC, Ballester F, Gonzalez Sanchez A, Almela Quilis A, Colomer Rubio E and Penarroja Otero C (2008) Epidemiology of sepsis in the Valencian Community (Spain), 1995-2004. Infect Control Hosp Epidemiol 29, 630-634   DOI
4 Angus DC and Wax RS (2001) Epidemiology of sepsis: an update. Crit Care Med 29, S109-116   DOI
5 Thachil J, Toh CH, Levi M and Watson HG (2012) The withdrawal of Activated Protein C from the use in patients with severe sepsis and DIC [Amendment to the BCSH guideline on disseminated intravascular coagulation]. Br J Haematol 157, 493-494   DOI
6 Bhatia M, He M, Zhang H and Moochhala S (2009) Sepsis as a model of SIRS. Front Biosci 14, 4703-4711   DOI
7 Tracey KJ, Fong Y, Hesse DG et al (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662-664   DOI
8 Wang H, Yang H, Czura CJ, Sama AE and Tracey KJ (2001) HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164, 1768-1773   DOI
9 Bianchi ME and Agresti A (2005) HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 15, 496-506   DOI
10 Gibot S, Massin F, Cravoisy A et al (2007) High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 33, 1347-1353   DOI
11 Ulloa L and Tracey KJ (2005) The "cytokine profile": a code for sepsis. Trends Mol Med 11, 56-63   DOI
12 Bae JS and Rezaie AR (2011) Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood 118, 3952-3959   DOI
13 Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A et al (2005) Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33, 564-573   DOI
14 Bae JS (2012) Role of high mobility group box 1 in inflammatory disease: Focus on sepsis. Arch Pharm Res 35, 1511-1523   DOI
15 O'Connor KA and Roth BL (2005) Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 4, 1005-1014   DOI
16 Li JX, Feng JM, Wang Y et al (2014) The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis 5, e1278   DOI
17 Padhy BM and Gupta YK (2011) Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med 57, 153-160   DOI
18 Liu X, Zhu F, Ma XH et al (2013) Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery. Curr Med Chem 20, 1646-1661   DOI
19 van Beijnum JR, Buurman WA and Griffioen AW (2008) Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11, 91-99   DOI
20 Diehl KH, Hull R, Morton D et al (2001) A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 21, 15-23   DOI
21 El Gazzar M (2007) HMGB1 modulates inflammatory responses in LPS-activated macrophages. Inflamm Res 56, 162-167   DOI
22 Mullins GE, Sunden-Cullberg J, Johansson AS et al (2004) Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scand J Immunol 60, 566-573   DOI
23 Czura CJ, Yang H and Tracey KJ (2003) High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor. J Infect Dis 187 Suppl 2, S391-396   DOI
24 Palumbo R, Galvez BG, Pusterla T et al (2007) Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 179, 33-40   DOI
25 Lee W, Ku SK, Lee YM and Bae JS (2014) Anti-septic effects of glyceollins in HMGB1-induced inflammatory responses in vitro and in vivo. Food Chem Toxicol 63, 1-8   DOI
26 Qin YH, Dai SM, Tang GS et al (2009) HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J Immunol 183, 6244-6250   DOI
27 Sun C, Liang C, Ren Y et al (2009) Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Res Cardiol 104, 42-49   DOI
28 Luo Y, Li SJ, Yang J, Qiu YZ and Chen FP (2013) HMGB1 induces an inflammatory response in endothelial cells via the RAGE-dependent endoplasmic reticulum stress pathway. Biochem Biophys Res Commun 438, 732-738   DOI
29 Erlandsson Harris H and Andersson U (2004) Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 34, 1503-1512   DOI
30 Park JS, Gamboni-Robertson F, He Q et al (2006) High mobility group box 1 protein interacts with multiple Tolllike receptors. Am J Physiol Cell Physiol 290, C917-924   DOI
31 Yang EJ, Ku SK, Lee W et al (2013) Barrier protective effects of rosmarinic acid on HMGB1-induced inflammatory responses in vitro and in vivo. J Cell Physiol 228, 975-982   DOI
32 Astiz ME and Rackow EC (1998) Septic shock. Lancet 351, 1501-1505   DOI